Wutah pendapatan taun lumaku: Zevra Corp (ZVRA)

Logo perusahaan publik Zevra Corp (ZVRA)

Zevra Therapeutics (ZVRA) is developing therapies for rare pathologies through partnerships with scientific foundations. An environmental approach and bioethics in drug development support the TTM revenue growth trajectory compared to last year, where the indicator remains around 75.00. Business stability is ensured by diversified supply chains for specific components, guaranteeing the uninterrupted distribution of medications.

Zevra Therapeutics (ZVRA): Wutah pendapatan YoY sajrone 12 wulan kepungkur saka 11.02.2024 nganti 18.11.2026

Zevra Corp (ZVRA) - rincian metrik lan laporan keuangan

- rega saham lan target rega konsensus:
- indikator kapitalisasi bursa perusahaan:
Pambiji fundamental perusahaan:Zevra Corp (ZVRA)
Produk dadi Kempharm

Zevra Therapeutics (ZVRA) maintains absolute pricing power within the essential rare disease medication segment, ensuring high cash flow stability. This metric measures the percentage change in revenue over the last twelve months relative to the same period last year, while the TTM revenue growth rate allows investors to filter out short-term volatility and assess the long-term effectiveness of asset commercialization.

Pesaing Zevra Therapeutics (ZVRA)